Advertisement


Muhit Özcan, MD, on DLBCL: Early Results on Zilovertamab Vedotin

2023 ASCO Annual Meeting

Advertisement

Muhit Özcan, MD, of Turkey’s Ankara University School of Medicine, discusses phase II findings from the waveLINE-004 study. It showed that the antibody-drug conjugate zilovertamab vedotin had clinically meaningful antitumor activity in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who experienced disease progression after, or have been ineligible for, autologous stem cell transplantation and/or chimeric antigen receptor T-cell therapy (Abstract 7531).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Muhit Özcan, MD: Treatment options are limited for patients with relapsed or refractory diffuse large B-cell lymphoma who are ineligible for or who have disease progression after autologous stem cell transplant and CAR T-cell therapy. ROR1 is an oncofetal transmembrane protein that's expressed in various hematological malignancies, including diffuse large B-cell lymphomas. Zilovertamab vedotin is an antibody drug conjugate compressing an anti-ROR1 monoclonal antibody plus a cleavable linker and the anti-microtubule cytotoxin monomethyl auristatin E. Here, we present early results from the single-arm, open label, phase-II waveLINE-004 study, which is designed to evaluate the efficacy and safe zilovertamab vedotin in patients with relapsed or refractory diffused large B-cell lymphoma who are ineligible for or who have disease progression after autologous stem cell transplant or after CAR T-cell therapy. Patients in waveLINE-004 received zilovertamab vedotin at 2.5 milligram per kilogram intravenously every three weeks. The primary endpoint was objective response rate, and the secondary endpoint was safety and tolerability. Safety was evaluated in all patients who received at least one cycle of study treatment, and efficacy was evaluated in all patients who received at least one dose of study treatment and had at least three months of follow-up. At the data cut-off, 40 patients had received treatment. The median age of patients was 68 years, 60% of patients had received three or more prior lines of therapy, 25% of patients had undergone prior stem cell transplant, and 28% of them had undergone prior CAR T-cell therapy. The objective response rate among the 20 patients with at least three months follow up was 30%, with two patients achieving a complete response and four patients achieving a partial response. An additional five patients had stable disease for a disease control rate of 55%, 95% confidence interval, 31.5 to 76.9%. Five patients had progressive disease and four patients could not be assessed. When change in target lesion size was evaluated, 13 or 20 patients had any reduction from baseline, and seven patients had a reduction in target lesion size of 50% or more. Treatment-related adverse events of any grade occurred in 70% of patients, most commonly diarrhea in 23, anemia in 20, neutropenia in 18, and neutrophil count decrease in 18% of patients. Grade 3 or 4 treatment-related adverse events occurred in 40% of patients and no that's due to treatment-related adverse events occurred. One patient discontinued treatment because of grade 3 treatment-related ketoacidosis. Treatment-related peripheral neuropathy occurred in 15% of patients over grade 1 or 2. No infusion-related reactions or treatment-related tumor lysis syndrome occurred. In summary, these earlier results from waveLINE-004 showed that zilovertamab vedotin had clinically-meaningful antitumor activity and manageable safety in patients with relapsed or refractory diffused large B-cell lymphoma who are ineligible for or who have had disease progression after autologous stem cell transplantation or after CAR T-cell therapy. These results support the continued investigation of zilovertamab vedotin in patients with relapsed or refractory diffused large B-cell lymphoma.

Related Videos

Skin Cancer

Allison Betof Warner, MD, PhD, and Zeynep Eroglu, MD, on Metastatic Melanoma: New Data on Dabrafenib, Trametinib, and Navitoclax

Allison Betof Warner, MD, PhD, of Stanford University Medical Center, and Zeynep Eroglu, MD, of H. Lee Moffitt Cancer Center and Research Institute, discusses phase II findings showing that in patients with BRAF-mutant metastatic melanoma, dabrafenib plus trametinib and navitoclax (DTN) was associated with a complete response rate of 20% and an overall response rate of 84%. Additionally, there was a trend toward improved overall survival in patients treated with DTN compared with dabrafenib plus trametinib alone; the difference in overall survival was more pronounced in patients with a smaller tumor burden (Abstract 9511).

Lymphoma

Jennifer L. Crombie, MD, on DLBCL: Real-World Outcomes With Novel Therapies in Relapsed or Refractory Disease

Jennifer L. Crombie, MD, of Dana-Farber Cancer Institute, discusses the historically poor outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Her study examined real-world data on the use of novel therapies in this population and found that outcomes with second- and third-line regimens of polatuzumab vedotin-piiq plus bendamustine and rituximab and tafasitamab plus lenalidomide remain suboptimal, with worse outcomes particularly after chimeric antigen receptor T-cell therapy (Abstract 7552).

Leukemia

Claire Roddie, PhD, MBChB, on B-ALL: Safety and Efficacy Data of Obecabtagene Autoleucel

Claire Roddie, PhD, MBChB, of University College London, discusses results of the FELIX study, which showed that the second-generation chimeric antigen receptor (CAR) T-cell therapy obecabtagene autoleucel is safe for adults with relapsed or refractory B-cell acute lymphoblastic leukemia, even those with a high burden of disease. This agent yielded high rates of complete response and ongoing CAR T-cell persistence in most patients whose disease responded (Abstract 7000).

Gynecologic Cancers
Immunotherapy

Bradley J. Monk, MD, on Cervical Cancer: Findings on Pembrolizumab Plus Chemotherapy

Bradley J. Monk, MD, of the University of Arizona, Phoenix, and Creighton University, discusses phase III findings from the KEYNOTE-826 study of overall survival results in patients with persistent, recurrent, or metastatic cervical cancer. Study participants received first-line treatment of pembrolizumab plus chemotherapy, with or without bevacizumab, which reduced the risk of death by up to 40% in three different subsets of patients (Abstract 5500).

Lymphoma

Nirav N. Shah, MD, on DLBCL: New Data on Split-Dose R-CHOP for Older Patients

Nirav N. Shah, MD, of the Medical College of Wisconsin, discusses phase II results showing that split-dose R-CHOP offers older patients with diffuse large B-cell lymphoma (DLBCL) an equivalent dose intensity as R-CHOP-21 through a fractionated dosing schedule, improving tolerability. At the end of treatment for these older patients, a complete response rate of 71% was comparable to outcomes with R-CHOP in younger patients with the disease (Abstract 7554).

Advertisement

Advertisement




Advertisement